Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 16/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL398876 | 0.88 | SMN1; SMN2 (0.47) | MEN1POLBKMT2ASMN1; SMN2NPSR1 | |
| SCHEMBL402703 | 0.80 | SMN1; SMN2 (0.49) | MEN1POLBKMT2ASMN1; SMN2KDM4E | |
| SCHEMBL399833 | 0.78 | PIK3CA (0.46) | NAMPTMEN1KMT2ASMN1; SMN2NPSR1 | |
| SCHEMBL3196708 | 0.77 | SMN1; SMN2 (0.44) | NAMPTMEN1POLBKMT2ASMN1; SMN2 | |
| SCHEMBL3201054 | 0.76 | MEN1 (0.44) | MEN1KMT2ASMN1; SMN2NPSR1PIK3CA | |
| SCHEMBL3199774 | 0.75 | SCN1A (0.43) | MEN1POLBKMT2ASMN1; SMN2NPSR1 | |
| SCHEMBL4253076 | 0.74 | NPC1 (0.45) | MEN1POLBKMT2ASMN1; SMN2NPSR1 | |
| SCHEMBL3201152 | 0.73 | NPC1 (0.46) | MEN1KMT2ASMN1; SMN2NPSR1PIK3CA | |
| SCHEMBL3734452 | 0.73 | NAMPT (0.43) | NAMPTPIK3CAMTORKDM4EALOX15 | |
| SCHEMBL399267 | 0.73 | RORC (0.48) | MEN1POLBKMT2ASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1959947-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | Cytokinetics, Inc. (US) | 2008-08-27 | — | — | EP | claimed |
| US-20070197505-A1 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. | 2007-08-23 | — | — | US | claimed |
| WO-2007075377-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2007-07-05 | — | — | WO | claimed |
| US-20090247544-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INC. | 2009-10-01 | — | — | US | disclosed |
| EP-1959947-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | Cytokinetics, Inc. (US) | 2008-08-27 | — | — | EP | disclosed |
| US-20070197505-A1 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. | 2007-08-23 | — | — | US | disclosed |
| WO-2007075377-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197505-A1 | Certain chemical entities, compositions and methods | TNNC1, TNNI3, TNNT2 | NAMPT 2884/4885MEN1 4493/4885POLB 2656/4885 |
| US-20090247544-A1 | Certain Chemical Entities, Compositions and Methods | TNNC1, TNNI3, TNNT2 | NAMPT 2884/4885MEN1 4493/4885POLB 2656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.